AR009990A1 - Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen - Google Patents

Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen

Info

Publication number
AR009990A1
AR009990A1 ARP970104749A ARP970104749A AR009990A1 AR 009990 A1 AR009990 A1 AR 009990A1 AR P970104749 A ARP970104749 A AR P970104749A AR P970104749 A ARP970104749 A AR P970104749A AR 009990 A1 AR009990 A1 AR 009990A1
Authority
AR
Argentina
Prior art keywords
tace
disease
independently selected
membered heteroaryl
heteroaryl ring
Prior art date
Application number
ARP970104749A
Other languages
English (en)
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of AR009990A1 publication Critical patent/AR009990A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Inhibidores no peptídicos de bajo peso molecular de las metaloproteinasas de matriz (por ejemplo, gelatinasas, estromelisinas y colagenasas) y de laenzima conversora de TNF - alfa (TACE, enzima de conversion de factor alfa de necrosis tumoral) que son utiles para el tratamiento de enfermedades en lascuales intervienen estas enzimas, tales como la artritirs, la metástasis y desarrollo de tumores, alangiogénesis, al ulceracion de tejidos, lacicatrizacion anormal de heridas, enfermedad periodontal, enfermedad osea, proteinuria, enfermedad de aneurisma aortico, pérdida degenerativa de cartílagoposterior a lesion traumática de las articulaciones, enfermedades desmielinizantes del sistema nervioso, rechazo de injertos,caquexia, anorexia,inflamacion, fiebre resistencia a la insulina, choque séptico, insuficiencia cardíaca congestiva, enfermedad inflamatoria del sistema nervioso central,enfermedad inflamatoria intestinal, infeccion por HIV, degeneracion macularasociada a la edad, retinopatía diabética, vitreorretinopatía proliferativa,retinopatía de la prematuridad, inflamacion ocular, queratocono, síndrome de Sjogren, miopía, tumores oculares, angiogénesis/ neovascularizacion ocular. Losácidos orto-sulfonamido arilhidroxámicos inhibidores de TACE y MMP están representados por la formula (I) en la cual la porcion de ácido hidroxámico yla porcion sulfonamido están unidas a los carbonos adyacentes del grupo A donde A es un anillo heteroarilo de 5 a 6 miembros con 1 a 3 heteroátomosindependientemente seleccionados entre N, O y S fusionado o un anillo heteroarilo de 5-6 miembros que tiene de 1 a 3 heteroátomos independientementeseleccionados entre N, O y S fusionado o un anillo heteroarilo de 5-6 miembros que tiene de 1 a 3 heteroátomos independientemente seleccionados entre N, O y S
ARP970104749A 1996-10-16 1997-10-15 Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen AR009990A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73200496A 1996-10-16 1996-10-16

Publications (1)

Publication Number Publication Date
AR009990A1 true AR009990A1 (es) 2000-05-17

Family

ID=24941797

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970104749A AR009990A1 (es) 1996-10-16 1997-10-15 Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen

Country Status (4)

Country Link
AR (1) AR009990A1 (es)
AU (1) AU743901B2 (es)
WO (1) WO1998016514A1 (es)
ZA (1) ZA979235B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548524B2 (en) * 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
EP0934300B1 (en) * 1996-10-16 2002-12-18 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU760218B2 (en) * 1997-10-06 2003-05-08 American Cyanamid Company The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
AR022424A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos ortosulfonamido acetilenico e hidroxamico biciclico heteroarilo amido de acido fosfinico como inhibidores tace, composicionfarmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
BR0007784A (pt) 1999-01-27 2002-02-05 American Cyanamid Co Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
AR035311A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
AU3385401A (en) * 2000-02-21 2001-09-03 Astrazeneca Ab Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents
RU2283306C2 (ru) 2000-02-21 2006-09-10 Астразенека Аб Пиперидин- и пиперазинзамещенные n-гидроксиформамиды в качестве ингибиторов металлопротеиназ
US6465508B1 (en) 2000-02-25 2002-10-15 Wyeth Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
AR027943A1 (es) * 2000-02-25 2003-04-16 Wyeth Corp Acidos orto-sulfonamido aril hidroxamicos como inhibidores de metaloproteinasa de matriz y preparacion de los mismos
AU2001250571A1 (en) * 2000-04-28 2001-11-12 P.N. Gerolymatos S.A. Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US6436629B1 (en) * 2000-10-27 2002-08-20 The Regents Of The University Of California Modulating angiogenesis
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
CA2468761A1 (en) * 2001-10-31 2003-05-08 Morphochem Aktiengesellschaft Fuer Kombinatorische Chemie Novel anticancer compounds
EP1440057A1 (en) 2001-11-01 2004-07-28 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
JP2006503008A (ja) * 2002-08-13 2006-01-26 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリクスメタロプロテイナーゼ阻害物質としての４−ヒドロキシキノリン誘導体
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
TW200418825A (en) 2002-12-16 2004-10-01 Hoffmann La Roche Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
US20080207673A1 (en) * 2005-05-04 2008-08-28 Michel Xilinas Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins
CA2691888A1 (en) * 2007-06-25 2008-12-31 Boehringer Ingelheim International Gmbh New chemical compounds
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
FR2947270B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US8513421B2 (en) 2010-05-19 2013-08-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
ES2695533T3 (es) 2016-02-01 2019-01-08 Galderma Res & Dev Compuestos de bencenosulfonamida, método para su síntesis y uso de los mismos en medicina y cosméticos
US20210393632A1 (en) 2018-10-04 2021-12-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
EP0934300B1 (en) * 1996-10-16 2002-12-18 American Cyanamid Company The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors

Also Published As

Publication number Publication date
WO1998016514A1 (en) 1998-04-23
AU4980697A (en) 1998-05-11
ZA979235B (en) 1999-04-15
AU743901B2 (en) 2002-02-07

Similar Documents

Publication Publication Date Title
AR009990A1 (es) Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen
AR008677A1 (es) Acidos orto-sulfonamido heteroaril hidroxamicos como inhibidores de la metalproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos y composicion farmaceutica que los contiene
AR008676A1 (es) Acidos beta-sulfonamido hidrosamicos como inhibidores de la metaloproteinasa de matriz y tace, uso de los mismos en la preparacion de unmedicamento y una composicion farmaceutica que los contienen
AR009382A1 (es) Derivados de acidos orto-sulfonamido aril hidroxamicos como inhibidores de la metaloproteinasa de matriz y tace, composiciones que los contienen y uso delos mismos para la preparacion de un medicamento.
RU2324684C2 (ru) Пиримидиновые производные
DK0871439T3 (da) Substituerede (aryl, heteroaryl, arylmethyl eller heteroarylmethyl) hydroxamsyreforbindelser
BRPI0408251A (pt) compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
NO20021728D0 (no) Pyrimidin-derivater
BR9813651A (pt) Compostos antipicornavirais e métodos para o seu uso e preparação
EA200600975A1 (ru) Конденсированные гетероциклические соединения, применимые для лечения ожирения и расстройств центральной нервной системы
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
AR032607A1 (es) Composiciones farmaceuticas que contienen sales de hidroxieicosatetraenoato, y el uso de las mismas para la manufactura de un medicamento para el tratamiento de desordenes del ojo seco
AR022423A1 (es) Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
MX2024002696A (es) Derivados del acido 2-amino-5,5-dimetilhexanoico como moduladores de sortilina para su uso en el tratamiento de enfermedades del sistema nervioso central.
SE8406201L (sv) Penicillansyraderivat
SE8700714D0 (sv) Anvendning av substituerade 4-fenyl-4-oxo-2-butensyraderivat for framstellning av lekemedel for behandling av sjukdomar i matsmeltningskanalen och som antiulcerost lekemedel
AR041481A1 (es) Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
IL166103A0 (en) Pyrrolidine derivatives and their use
BR9909267A (pt) C11 oximila e prostaglandinas hidroxilamino úteis como medicamentos
AR022405A1 (es) Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos
NO155135C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-amino-1-benzoxepinderivater.
ATE73807T1 (de) Neue benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte.
KR102042411B1 (ko) 데커신 유도체를 포함하는 결핵 예방 또는 치료용 조성물
UA26390A (uk) 5- або 6-заміщеhі складhі ефіри бета-карболіh-3-карбоhової кислоти, які проявляють психотропhу активhість, та фармацевтичhий препарат для лікуваhhя психотропhих захворюваhь
FR2375225A1 (fr) Nouvelles o-propyloximes substituees basiquement, leur procede de preparation et leur emploi comme medicaments